In addition to the compelling need to generate strong and unambiguous clinical evidence, this new AUTOSTEM publication by Jelena Ochs, Frank Barry, Robert Schmitt and Mary Murphy describes AUTOSTEM in the context of the major technical gaps in manufacturing that must be closed before the promise for the treatment of chronic and debilitating diseases by MSCs is realised. ‘Chief among these is the development of manufacturing platforms for cell products that are efficient, cost-effective and reproducible. Automated, robotic and closed production systems will provide the most efficient manufacturing strategy. Here, we describe advances in automation for the clinical-scale production of MSCs and challenges associated with translating from lab-scale to automated large-scale manufacturing processes.’
Read the full publication in Gene and Cell Therapy Insights here.
Submitted for review: Oct 3 2017 Published: Nov 21 2017
Citation: Cell Gene Therapy Insights 2017; 3(8), 739-748.